195 related articles for article (PubMed ID: 18287274)
1. 18F-labeled BBN-RGD heterodimer for prostate cancer imaging.
Li ZB; Wu Z; Chen K; Ryu EK; Chen X
J Nucl Med; 2008 Mar; 49(3):453-61. PubMed ID: 18287274
[TBL] [Abstract][Full Text] [Related]
2. 64Cu-NO2A-RGD-Glu-6-Ahx-BBN(7-14)NH2: a heterodimeric targeting vector for positron emission tomography imaging of prostate cancer.
Jackson AB; Nanda PK; Rold TL; Sieckman GL; Szczodroski AF; Hoffman TJ; Chen X; Smith CJ
Nucl Med Biol; 2012 Apr; 39(3):377-87. PubMed ID: 22226021
[TBL] [Abstract][Full Text] [Related]
3. In Vivo Cancer Dual-Targeting and Dual-Modality Imaging with Functionalized Quantum Dots.
Hu K; Wang H; Tang G; Huang T; Tang X; Liang X; Yao S; Nie D
J Nucl Med; 2015 Aug; 56(8):1278-84. PubMed ID: 26112023
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer.
Richter S; Wuest M; Krieger SS; Rogers BE; Friebe M; Bergmann R; Wuest F
Nucl Med Biol; 2013 Nov; 40(8):1025-34. PubMed ID: 23969085
[TBL] [Abstract][Full Text] [Related]
5. PET of tumors expressing gastrin-releasing peptide receptor with an 18F-labeled bombesin analog.
Dijkgraaf I; Franssen GM; McBride WJ; D'Souza CA; Laverman P; Smith CJ; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2012 Jun; 53(6):947-52. PubMed ID: 22570329
[TBL] [Abstract][Full Text] [Related]
6. Novel
Lucente E; Liu H; Liu Y; Hu X; Lacivita E; Leopoldo M; Cheng Z
Bioconjug Chem; 2018 May; 29(5):1595-1604. PubMed ID: 29587479
[TBL] [Abstract][Full Text] [Related]
7. Clinical Translation of a Dual Integrin αvβ3- and Gastrin-Releasing Peptide Receptor-Targeting PET Radiotracer, 68Ga-BBN-RGD.
Zhang J; Niu G; Lang L; Li F; Fan X; Yan X; Yao S; Yan W; Huo L; Chen L; Li Z; Zhu Z; Chen X
J Nucl Med; 2017 Feb; 58(2):228-234. PubMed ID: 27493267
[TBL] [Abstract][Full Text] [Related]
8. GRPR-selective PET imaging of prostate cancer using [(18)F]-lanthionine-bombesin analogs.
Carlucci G; Kuipers A; Ananias HJ; de Paula Faria D; Dierckx RA; Helfrich W; Rink R; Moll GN; de Jong IJ; Elsinga PH
Peptides; 2015 May; 67():45-54. PubMed ID: 25797109
[TBL] [Abstract][Full Text] [Related]
9. 177Lu-labeled RGD-BBN heterodimeric peptide for targeting prostate carcinoma.
Jiang L; Miao Z; Liu H; Ren G; Bao A; Cutler CS; Shi H; Cheng Z
Nucl Med Commun; 2013 Sep; 34(9):909-14. PubMed ID: 23708872
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of 188Re-MAG2-RGD-bombesin for potential prostate cancer therapy.
Cui L; Liu Z; Jin X; Jia B; Li F; Wang F
Nucl Med Biol; 2013 Feb; 40(2):182-9. PubMed ID: 23199569
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer.
Lears KA; Ferdani R; Liang K; Zheleznyak A; Andrews R; Sherman CD; Achilefu S; Anderson CJ; Rogers BE
J Nucl Med; 2011 Mar; 52(3):470-7. PubMed ID: 21321264
[TBL] [Abstract][Full Text] [Related]
12. A new (68)Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging.
Pan D; Xu YP; Yang RH; Wang L; Chen F; Luo S; Yang M; Yan Y
Amino Acids; 2014 Jun; 46(6):1481-9. PubMed ID: 24633452
[TBL] [Abstract][Full Text] [Related]
13. 99mTc-labeled RGD-BBN peptide for small-animal SPECT/CT of lung carcinoma.
Liu Z; Huang J; Dong C; Cui L; Jin X; Jia B; Zhu Z; Li F; Wang F
Mol Pharm; 2012 May; 9(5):1409-17. PubMed ID: 22452411
[TBL] [Abstract][Full Text] [Related]
14. Imaging integrin αvβ 3 and NRP-1 positive gliomas with a novel fluorine-18 labeled RGD-ATWLPPR heterodimeric peptide probe.
Wu H; Chen H; Pan D; Ma Y; Liang S; Wan Y; Fang Y
Mol Imaging Biol; 2014 Dec; 16(6):781-92. PubMed ID: 25001194
[TBL] [Abstract][Full Text] [Related]
15. A heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors.
Durkan K; Jiang Z; Rold TL; Sieckman GL; Hoffman TJ; Bandari RP; Szczodroski AF; Liu L; Miao Y; Reynolds TS; Smith CJ
Nucl Med Biol; 2014 Feb; 41(2):133-9. PubMed ID: 24480266
[TBL] [Abstract][Full Text] [Related]
16. Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2.
Zhang X; Xiong Z; Wu Y; Cai W; Tseng JR; Gambhir SS; Chen X
J Nucl Med; 2006 Jan; 47(1):113-21. PubMed ID: 16391195
[TBL] [Abstract][Full Text] [Related]
17. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, preclinical, and initial clinical evaluation of integrin α
Wen X; Wang R; Xu P; Shi M; Shang Q; Zeng X; Zeng X; Liu J; Wang X; Zhu Z; Guo Z; Chen X; Zhang J
Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):2023-2035. PubMed ID: 38376806
[TBL] [Abstract][Full Text] [Related]
19. Characterization and evaluation of DOTA-conjugated Bombesin/RGD-antagonists for prostate cancer tumor imaging and therapy.
Stott Reynolds TJ; Schehr R; Liu D; Xu J; Miao Y; Hoffman TJ; Rold TL; Lewis MR; Smith CJ
Nucl Med Biol; 2015 Feb; 42(2):99-108. PubMed ID: 25459113
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a technetium-99m labeled bombesin homodimer for GRPR imaging in prostate cancer.
Yu Z; Carlucci G; Ananias HJ; Dierckx RA; Liu S; Helfrich W; Wang F; de Jong IJ; Elsinga PH
Amino Acids; 2013 Feb; 44(2):543-53. PubMed ID: 22833158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
